Dolastatin 10 vs Apratoxin A
Head-to-head comparison of Dolastatin 10 (Dolastatin 10) and Apratoxin A (Apratoxin A) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Dolastatin 10 | Apratoxin A |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Dolastatin 10 | Apratoxin A |
| Molecular Weight | 771.0 Da | N/A |
| Half-Life | N/A | N/A |
| Amino Acids | 5 | N/A |
| Typical Dose | N/A in humans; subnanomolar to low-nanomolar in vitro | N/A in humans; nanomolar in vitro |
| Route | Intravenous | Intraperitoneal / Intravenous (preclinical) |
| Purity | ≥98% | ≥98% |
| Studies Count | 300 | 140 |
| Research Status | Pre-clinical | Pre-clinical |
Dolastatin 10 Benefits
- ✓antineoplastic
- ✓microtubule disruption
- ✓antimitotic
- ✓ADC payload scaffold
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
Dolastatin 10 Dosing
research-grade in vitro nanomolar use|early IV oncology exploration|no approved dosing regimen
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
Dolastatin 10 Side Effects
- ⚠peripheral neuropathy
- ⚠neutropenia
- ⚠fatigue
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Research Overview
Dolastatin 10
Dolastatin 10 became famous for extreme cytotoxic potency and its ability to block tubulin polymerization. Although the native compound itself did not become a standard therapy, it inspired a major class of clinically important auristatin-based payloads.
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.